{
    "nctId": "NCT00616967",
    "briefTitle": "Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer",
    "officialTitle": "A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 68,
    "primaryOutcomeMeasure": "Pathological Complete Response (pCR) Rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed infiltrating ductal breast cancer by core needle biopsy\n\n  * Mixed ductal and lobular disease allowed\n  * Infiltrating lobular cancer allowed in the run-in portion only\n* Unresected, clinically measurable disease, meeting 1 of the following clinical staging criteria:\n\n  * T2, T3, or T4 lesion, any N, M0\n  * T1c, N1-3,M0\n* Patients with skin metastases to the ipsilateral breast for whom chemotherapy is planned prior to definitive surgery are eligible for the primary study portion\n* HER2-negative disease\n* Hormone receptor status\\* meeting 1 of the following criteria:\n\n  * Estrogen receptor (ER)-negative and progesterone receptor (PR)-negative\n  * ER-positive (grade II or III) and PR-positive or PR-negative NOTE: \\*Any ER or PR status for the run-in portion\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-1\n* Menopausal status not specified\n* ANC \u2265 1,500/mm\u00b3\n* Platelet count \u2265 150,000/mm\u00b3\n* Hemoglobin \u2265 9 g/dL\n* Creatinine \u2264 1.5 times the upper limit of normal (ULN)\n* Creatinine clearance \u2265 50 mL/min\n* Total bilirubin normal\n* AST(SGOT) and ALT(SGPT) \u2264 2.5 times (ULN)\n* alkaline phosphatase \u2264 2.5 times ULN\n* PT such that INR \u2264 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and PTT \u2264 ULN\n* Adequate cardiac function defined as no evidence of PR prolongation or AV block on baseline electrocardiogram (ECG)\n* Willing to use effective, non-hormonal contraception while on treatment and for at least 3 months thereafter\n* Not pregnant or nursing\n* No pre-existing peripheral neuropathy \u2265 grade 2\n* No history of severe hypersensitivity reaction to any drug formulated with polysorbate 80 or to E. coli-derived products\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat\n* No medical condition which, in the opinion of the investigator, puts the patient at risk of potentially serious complications while on this therapy\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 4 weeks since prior valproic acid or other histone deacetylase inhibitor\n* No prior chemotherapy, radiotherapy, or endocrine therapy for this cancer\n\n  * Prior tamoxifen or raloxifene or another agent for prevention of breast cancer allowed as long as the patient has discontinued the treatment \u2265 1 month prior to baseline study biopsy\n* No systemic treatment for prior cancer within the past 5 years (primary study portion)\n* No prior or ongoing systemic treatment for this cancer (primary study portion)\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent histone deacetylase inhibitor\n* No other concurrent chemotherapy, antiestrogen therapy, radiotherapy, or other investigational systemic therapy\n* No other concurrent biologic therapy\n* No other concurrent investigational drugs",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}